Trial Profile
A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Methotrexate; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RADIATE
- Sponsors Roche
- 06 Jun 2020 Results of pooled analysis from seven studies (OPTION, RADIATE, TOWARD, LITHE, ACT-RAY, ADACTA and BREVACTA) presented at the 21st Annual Congress of the European League Against Rheumatism.
- 31 Jan 2018 Results (n=299) assessing tissue degradation in rhuematoid arthritis patients with previous inadequate response to anti-TNFalpha therapy published in the Clinical and Experimental Rheumatology.
- 08 Nov 2017 Results of two phase III trials (NCT00106522 and NCT00106535) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting